doctors are worried about prescribing glp 1 GLP-1 weight-loss drugs revolutionary – and they're exposing America's healthcare crisis | David A Kessler Doctors' GLP-1 stigma keeps many

Staying toward the higher end of this range can help support muscle maintenance during weight loss

This is now the second trial suggesting that the two drugs are not exactly on the same level

A new study also suggests that patients taking semaglutide (Ozempic and Wegovy) may be at an increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION)

This receptor profile interferes with hypothalamic appetite regulation, reduces energy expenditure, and impairs peripheral insulin signaling

US state-level prevalence of adult obesity by race and ethnicity from 1990 to 2022 and forecasted to 2035, JAMA

It works for injectable GLP-1s Wegovy, Zepbound, Ozempic, Mounjaro, semaglutide, tirzepatide, and compounded forms and for oral GLP-1s including Rybelsus, oral Wegovy, Foundayo, and orforglipron